Correlation Between Lateralization Index of Adrenal Venous Sampling and Standardized Outcome in Primary Aldosteronism

Hironobu Umakoshi,1 Mika Tsuiki,1 Maki Yokomo-Umakoshi,1 Yoshiyu Takeda,1 Yoneda Takashi,2 Isao Kurihara,3 Hiroshi Itoh,3 Takayuki Katabami,4 Takamasa Ichijo,5 Norio Wada,6 Yui Shibayama,6 Takanobu Yoshimoto,6 Kenji Ashida,6 Yoshihiro Ogawa,6 Junji Kawashima,9 Masakatsu Sone,10 Nobuya Inagaki,10 Katsutoshi Takahashi,11 Minemori Watanabe,12 Yuichi Matsuda,13 Hiroki Kobayashi,14 Hirotaka Shibata,15 Kohei Kamemura,16 Michio Otsuki,17 Yuichi Fuji,18 Koichi Yamamoto,19 Atsushi Ogo,20 Shintaro Okamura,21 Shozo Miyauchi,22 Tomikazu Fukuoka,23 Shoichiro Izawa,24 Toshihiko Yanase,25 Shigeatsu Hashimoto,26 Masanobu Yamada,27 Yuichiro Yoshikawa,28 Tatsuya Kai,29 Tomoko Suzuki,30 Takashi Kawamura,31 and Mitsuhide Naruse1

1Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan; 2Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-0934, Japan; 3Department of Endocrinology, Metabolism and Nephrology, School of Medicine Keio University, Tokyo 160-8582, Japan; 4Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama 241-0811, Japan; 5Department of Endocrinology and Metabolism, Saiseikai Yokohamashi Tobu Hospital, Yokohama 230-8765, Japan; 6Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan; 7Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Tokyo 113-8510, Japan; 8Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Fukuoka 812-8582, Japan; 9Department of Metabolic Medicine, Faculty of Life Science, Kumamoto University, Kumamoto University, Kumamoto 860-8556, Japan; 10Department of Diabetes, Endocrinology and Nutrition Kyoto University, Kyoto 606-8309, Japan; 11Division of Metabolism, Shouwa General Hospital, Tokyo 187-0002, Japan; 12Department of Endocrinology and Metabolism, Osaka City Hospital, Osaka 544-8553, Japan; 13Department of Cardiology, Senda City Hospital, Senda 669-1321, Japan; 14Division of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Tokyo 173-8610, Japan; 15Department of Endocrinology, Rheumatology and Nephropathy, Faculty of Medicine, Oita University, Yufu 879-5593, Japan; 16Department of Cardiology, Shinko Hospital, Kobe 651-0072, Japan; 17Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; 18Department of Cardiology, JR Hiroshima Hospital, Hiroshima 732-0057, Japan; 19Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan; 20Clinical Research Institute, National Hospital Organization Kyusu Medical Center, Fukuoka 810-0065, Japan; 21Department of Endocrinology, Tenryouzen Hospital, Tenri 632-8552, Japan; 22Department of Internal Medicine, Uwajima City Hospital, Uwajima 798-8510, Japan; 23Department of Internal Medicine, Matsuyama Red Cross Hospital, Matsuyama 790-8524, Japan; 24Department of Endocrinology and Metabolism, Tottori University Hospital, Tottori 683-8503, Japan; 25Department of Endocrinology and Diabetes Mellitus, Faculty of Medicine, Fukuoka University 814-0133; 26Division of Nephrology, Hypertension, Endocrinology, and Diabetology/Metabolism, Fukushima Medical University Hospital, Fukushima 960-1247, Japan; 27Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi 371-0034, Japan; 28Department of Endocrinology and Diabetes Mellitus, Misato Kenua Hospital, Misato 341-8555, Japan; 29Department of Cardiology, Saiseikai Tondabayashi Hospital, Tondabayashi 584-0082, Japan; 30Department of Public Health, School of Medicine, International University of Health and Welfare, Narita 286-8686, Japan; and 31Kyoto University Health Service, Kyoto 606-8397, Japan

Abbreviations: ARC, active renin concentration; ARR, aldosterone to renin ratio; AVS, adrenal venous sampling; CLR, contralateral aldosterone suppression ratio; LI, lateralization index; PA, primary aldosteronism; PAC, plasma aldosterone concentration; PRA, plasma renin activity; PASO, Primary Aldosteronism Surgical Outcome.
Objectives: The aim of this study was to investigate the impact of adrenal venous sampling (AVS) lateralization cutoffs on surgical outcomes.

Patients and Methods: Cosyntropin-stimulated AVS was used to guide surgical management of 377 patients with primary aldosteronism (PA) who were evaluated 6 months after surgery.

Main Outcome Measures: The proportion of patients that achieved clinical benefit and complete biochemical success based on the AVS aldosterone lateralization index (LI) was determined.

Results: Clinical benefit was achieved in 29 of 47 patients with an LI between 2 and 4, in 66 of 101 with an LI between 4 and 10, and in 158 of 203 with an LI > 10 (P < 0.01 for trend). Complete biochemical success was achieved in 27 of 42 with an LI between 2 and 4, in 60 of 76 with an LI between 4 and 10, and in 127 of 155 with an LI > 10 (P = 0.024 for trend). After adjustment for confounders and using those patients with an LI between 2 and 4 as a reference, a clinical benefit was associated only with those with an LI > 10 (OR, 2.30; 95% CI, 1.03 to 5.16), whereas complete biochemical success was associated with those with an LI between 4 and 10 (OR, 2.83; 95% CI, 1.14 to 7.01) or LI > 10 (OR, 3.55; 95% CI, 1.47 to 8.55).

Conclusions: Difference of clinical outcome was relatively small when strict LI diagnostic threshold was used; biochemical cure was sufficiently achieved when an LI > 4 was used. Our study by standardized outcome measures validated that an LI > 4 may be appropriate for determining unilateral disease in PA.
PA who were adrenalectomized based on cosyntropin-stimulated AVS findings and who underwent follow-up assessments of outcome (clinical and/or biochemical) at 6 months after surgery between January 2006 and December 2016 at 28 participating JPAS centers in Japan. We excluded patients with unsuccessful AVS, those with bilateral aldosterone suppression [14, 15] during AVS (as a sampling error), and those with associated Cushing syndrome. Clinical findings including patients’ characteristics; biochemical, imaging, and AVS results were retrospectively obtained from the JPAS registry. A surgical indication was determined by each investigator based on AVS findings using the guidelines from the Japan Endocrine Society [16] and local reference criteria combined with the clinical background of the patients. This retrospective study was analyzed using the dataset valid in June 2017. The study was conducted according to clinical studies published by the Ministry of Health and Labor, Japan, and was approved by the ethics committee of the National Hospital Organization Kyoto Medical Center, as the project leader, and by the institutional ethics committees of the participating centers. This observational study was registered as UMIN ID 18756.

B. Diagnosis of PA

The diagnosis of PA was made in accordance with the guidelines of the Japan Endocrine Society [16] and the Japan Society of Hypertension [17]. PA was diagnosed by a ratio of plasma aldosterone concentration (PAC) (ng/dL) to plasma renin activity (PRA) (ng/mL/h) [aldosterone to renin ratio (ARR)] >20 and at least one positive result from confirmatory tests, including captopril-challenge, saline-infusion, furosemide-upright, and oral salt-loading. Antihypertensive medications were usually switched to calcium-channel blockers and/or α-adrenergic blockers, as appropriate, until the final diagnosis was made.

C. Adrenal Venous Sampling

AVS was performed in patients who opted for surgery. The details of the AVS procedure have been described previously [18]. In brief, adrenal blood samples were collected sequentially at 24 centers and at 4 centers where simultaneous catheterization was conducted. Cosyntropin was administered by bolus injection alone, bolus injection followed by continuous infusion, or continuous infusion alone throughout the procedure. Adrenal vein cannulation was defined as successful if the selectivity index was >5 [5, 16]. The selectivity index was defined as the ratio of the cortisol concentration in the adrenal vein to that in the inferior vena cava. The lateralization index (LI) was calculated by dividing the aldosterone to cortisol ratio in the dominant adrenal vein by that in the nondominant adrenal vein. The contralateral aldosterone suppression ratio (CLR) was calculated by dividing the aldosterone to cortisol ratio in the nondominant adrenal vein by that in the inferior vena cava. Bilateral aldosterone suppression [14, 15] was defined as an aldosterone to cortisol ratio in both the dominant and nondominant adrenal veins lower than that in the inferior vena cava.

D. Definition of Clinical and Biochemical Outcomes

Biochemical and clinical outcomes after unilateral adrenalectomy were evaluated based on the recent international Primary Aldosteronism Surgical Outcome (PASO) consensus. In brief, the biochemical outcome was determined by the postoperative ARR and serum potassium concentration; clinical outcome was determined by postoperative blood pressure. Biochemical and clinical outcomes were classified as complete, partial, or absent success based on the response to surgery. A clinical benefit was defined as either complete or partial success. Details of the outcome criteria have been described previously by Williams et al. [12].

E. Assay Methods

PAC and PRA were measured using commercial kits. PAC was determined by radioimmunoassay (SPAC-S Aldosterone kit; Fuji Rebio, Co., Ltd, Tokyo, Japan) at all centers. The
reference range of PAC in the supine position was 3.0 to 15.9 ng/dL. PRA was measured by radioimmunoassay or enzyme immunoassay. The reference range of PRA in the supine position was 0.3 to 2.9 ng/mL/h (PRA-FR RIA kit; Fuji Rebio, Co., Ltd.) at 16 of the study centers, 0.2 to 2.3 ng/mL/h (PRA EIA kit; Yamasa Co., Ltd., Choshi, Japan) at 8 centers, and 0.2 to 2.7 ng/mL/h (PRA RIA kit) at 3 centers. The plasma active renin concentration (ARC) was measured by immunoradiometric assay (Renin IRMA-FR kit; Fuji Rebio, Co., Ltd.) at one center. The ARC was converted to a PRA value and divided by 5 according to the Japan Endocrine Society guideline [16]; the PRA value was used for the analyses. The reference range of ARC in the supine position was 2.5 to 21.4 pg/mL.

F. Measurements and Statistical Analysis

Clinical and biochemical outcome was calculated with respect to the LI. We compared clinical characteristics between patients with and those without a surgical benefit. The LI was categorized into three groups: 2 to 4, 4 to 10, and >10. The reason for this classification is that, although an LI >4 is the most commonly used cutoff as a criterion for positivity, one-half of the centers involved in this study use more permissive cutoffs (LI 2 to 4) [19]. An LI of 10 was derived from the area under the receiver operating characteristic curve for evaluating a clinical benefit (Supplemental Fig. 1). The cutoff was determined as the value affording the optimal sensitivity and specificity (Youden index). For clinical utility, the LI value of 9.9 calculated from the analysis was changed to 10. We compared the baseline clinical characteristics among the three LI groups. We also compared the proportion of patients with surgical outcomes in terms of complete biochemical success and clinical benefit among the three LI groups.

A logistic regression analysis was performed to evaluate the effect of the AVS results on surgical outcome. The adjusted variables evaluated in the analysis (age, sex, body mass index, systolic blood pressure, antihypertensive medication use, estimated glomerular filtration rate, serum potassium concentration, plasma aldosterone concentration, and presence of diabetes mellitus) were selected according to previous reports [11, 12].

Statistical analyses were performed using EZR statistical software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [20]. Continuous variables were expressed as mean with the SD. Categorical variables were expressed as numbers and percentages. Continuous variables were analyzed using the Student t test and categorical variables using the Fisher exact test. Analysis of group difference used one-way ANOVA and the Fisher exact test with a post hoc Bonferroni analysis. All tests were two-tailed, with \( P < 0.05 \) indicating a significant difference.

2. Results

Between January 2006 and December 2016, 481 patients with PA who had been adrenalectomized based on cosyntropin-stimulated AVS findings and who had available follow-up data regarding clinical and/or biochemical outcomes 6 months after surgery were recruited. Of these, 104 patients were excluded from the current study for the following reasons: 71 with unsuccessful cosyntropin-stimulated AVS, 10 with Cushing syndrome, and 23 with bilateral aldosterone suppression during AVS. In total, 377 patients (351 with a clinical outcome, 273 with a biochemical outcome, and 247 with both outcomes) were analyzed in the current study. Of these, 52 patients had an LI between 2 and 4, 106 had an LI between 4 and 10, and 219 had an LI > 10 (Supplemental Fig. 2).

The clinical characteristics included a mean age of 53 years, nearly equivalent sex prevalence, moderate doses of antihypertensive medications used, and frequent hypokalemia (Table 1). Complete biochemical success was found in 214 (78.4%) and partial biochemical success in 31 (11.4%) of the 273 patients with biochemical outcome data (Fig. 1A). On the other hand, complete clinical success was observed in 95 (27.1%) and partial clinical success in 152 (43.3%) of the 234 patients with clinical outcome data; thus, 70% of patients achieved a clinical benefit (Fig. 1B).
The baseline characteristics of the participating patients evaluated with respect to the LI are summarized in Table 1. Substantial differences in 7 of 13 variables were found among 3 LI groups. A biochemical complete success was achieved in 27 of 42 (64.3%) with an LI between 2 and 4, in 60 of 76 (78.9%) with an LI between 4 and 10, and in 127 of 155 (81.9%) with an LI > 10 (P = 0.024 for trend) (Fig. 1A). A clinical cure was achieved in 10 of 47 (21.3%) patients with an LI between 2 and 4, in 22 of 101 (21.8%) with an LI between 4 and 10, and in 63/203 (31.0%) with an LI > 10 (P = 0.071 for trend); a clinical benefit was achieved in 29 of 47 (61.7%) patients with an LI between 2 and 4, in 60 of 101 (59.4%) with an LI between 4 and 10, and in 158 of 203 (77.8%) with an LI > 10 (P < 0.01 for trend) (Fig. 1B). Using a criterion for positivity of LI > 4, 187 of 231 (81%) showed a biochemical cure, whereas 85 of 304 (27.9%) showed a clinical cure and 218 of 304 (71.7%) patients showed a clinical benefit.

We performed a logistic regression analysis to determine the effect of AVS lateralization cutoffs on surgical outcome. In a univariate analysis, using the patients with an LI between 2 and 4 as the reference group, biochemical complete success and clinical benefits in terms of surgical outcomes were associated only those with an LI > 10 but not those with an LI between 4 and 10 (Table 2). After adjustment for confounders, a complete biochemical success was associated with both an LI between 4 and 10 (OR, 2.83; 95% CI, 1.14 to 7.01) and LI > 10 (OR, 3.55; 95% CI, 1.47 to 8.55) (Table 2), whereas a clinical benefit was associated with an LI > 10 (OR, 2.30; 95% CI, 1.03 to 5.16) but not with an LI between 4 and 10 (OR, 0.97; 95% CI, 0.45 to 2.10). A criterion for positivity of LI > 4 was associated with surgical outcomes in terms of the complete biochemical success, but not clinical benefit (Table 2). Additionally, we evaluated a criterion of CLR < 1 for surgical outcomes in terms of complete biochemical success and clinical benefit. Although a criterion for positivity of CLR < 1 showed a high proportion of complete success of biochemical outcome with equal to that of LI > 10, no substantial differences were found in patients with and without meeting a criterion of CLR < 1 for biochemical and clinical outcomes (Table 2).
3. Discussion

Our results demonstrated an association between AVS aldosterone lateralization cutoffs and surgical outcomes based on recent international criteria in unilateral adrenalectomized patients with PA. The major difference of the current study was to correlate the LI cutoff and clinical and biochemical outcomes after adrenal surgery using the PASO criteria [12]. The results provided evidence that LI cutoff of 4 is an adequate cutoff to determine unilateral

Figure 1. Biochemical and clinical outcomes of adrenalectomized patients with primary aldosteronism. The proportion of patients with outcomes in terms of biochemical and clinical outcomes was assessed with respect to the LI, which was categorized into three groups (2 to 4, 4 to 10, and >10). (A) Complete biochemical success was in nearly 80% of the patients and (B) clinical benefit was achieved in nearly 70%. There was a tendency for favorable biochemical and clinical outcomes with an increasing LI value [(A) \( P < 0.01 \) for trend for biochemical outcome, (B) \( P < 0.01 \) for clinical outcome]. Using LI > 4 as a criterion for positivity, (A) 187 of 231 (81%) patients showed complete biochemical success and (B) 218 of 304 (72%) patients showed a clinical benefit.

Table 2. Surgical Outcomes in Terms of Biochemical and Clinical Outcomes as Determined by AVS Findings in Unadjusted and Adjusted Analyses

| Biochemical Outcome | Patients | Complete Success (%) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---------------------|----------|----------------------|------------------------|----------------------|
| LI category         |          |                      |                        |                      |
| 2–4                 | 42       | 27 (64)              | 1.00 (reference)       | 1.00 (reference)     |
| 4–10                | 76       | 60 (79)              | 2.08 (0.90–4.82)       | 2.83 (1.14–7.01)     |
| >10                 | 155      | 127 (82)             | 2.52 (1.19–5.35)       | 3.55 (1.47–8.55)     |
| AVS criterion       |          |                      |                        |                      |
| LI < 4              | 42       | 27 (64)              | 1.00 (reference)       | 1.00 (reference)     |
| LI > 4              | 231      | 187 (81)             | 2.36 (1.16–4.81)       | 3.21 (1.44–7.18)     |
| CLR > 1             | 29       | 22 (76)              | 1.00 (reference)       | 1.00 (reference)     |
| CLR < 1             | 244      | 192 (79)             | 1.17 (0.48–2.90)       | 1.40 (0.54–3.66)     |
| Clinical outcome    | Patients | Benefits (%)         | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
| LI category         |          |                      |                        |                      |
| 2–4                 | 47       | 29 (61)              | 1.00 (reference)       | 1.00 (reference)     |
| 4–10                | 101      | 60 (59)              | 0.91 (0.45–1.85)       | 0.97 (0.45–2.10)     |
| >10                 | 203      | 158 (77)             | 2.18 (1.11–4.28)       | 2.30 (1.03–5.16)     |
| AVS criterion       |          |                      |                        |                      |
| LI < 4              | 47       | 29 (61)              | 1.00 (reference)       | 1.00 (reference)     |
| LI > 4              | 304      | 218 (72)             | 1.57 (0.83–2.98)       | 1.44 (0.70–2.99)     |
| CLR > 1             | 37       | 26 (70)              | 1.00 (reference)       | 1.00 (reference)     |
| CLR < 1             | 314      | 221 (70)             | 1.01 (0.48–2.12)       | 0.61 (0.27–1.40)     |

Adjusted for age, sex, body mass index, systolic blood pressure, defined daily dose of antihypertensive medications, estimated glomerular filtration rate, serum potassium concentration, plasma aldosterone concentration, and diabetes mellitus.
disease and to achieve good biochemical outcome, whereas the difference of clinical benefit for LI between 4 and 10 and that for LI > 10 was relatively small, although it was statistically significant. Our study by standardized outcome measure validated that an LI > 4 recommended by clinical guidelines [5] may be appropriate for determining unilateral disease in PA.

Before the recent international standardized criteria on surgical outcome of patients with PA were established [12], the postoperative outcomes of patients with PA were usually determined by a combination of blood pressure, hormone profiles, serum potassium levels, and occasionally pathological findings based on local reference criteria [11]. This is one of the reasons that resolution or improvement of PA has differed widely across studies that used different lateralization cutoffs of AVS. Although the receiver operating characteristic analysis showed an LI of 9.9 as the optimal cutoff (Youden index) for evaluating clinical outcome (Supplemental Fig. 1), the AUC (0.59; 95% CI, 0.53 to 0.66), which afforded a sensitivity of 65% and a specificity of 57%, was not sufficient because a tendency, rather than a clear association, for clinical and biochemical outcomes in patients with this LI value was detected (Fig. 1). The best cutoff for the AVS LI was therefore difficult to establish. Our results suggest that unilateral hyperaldosteronism may consist of heterogeneous etiologies.

An international survey of AVS (Adrenal Vein Sampling International Study) [19] reported that an LI > 4 is the most common criterion associated with cosyntropin-stimulated AVS. Considering that > 80% of patients can achieve complete success in terms of biochemical outcome determined by recent international standardized criteria with a commonly used criterion of LI > 4 (Fig. 1; Table 2), this cutoff is preferable when biochemical success is the goal. In the PASO study [12], PA patients with an LI > 4 showed preferable surgical outcomes in terms of biochemical than those with an LI < 4 in univariate analysis. In contrast, a higher LI value (>10) was needed to obtain an independent surgical benefit in terms of clinical outcome (Table 2). We used nine variables for a logistic regression analysis; these variables were reported by the associated factor for surgical outcome of PA [11, 12]. In addition, similar important differences of variables, especially in clinical outcome, between patients with and those without surgical benefit were seen in present study (Supplemental Table 1). In these confounders, age, body mass index, and systolic blood pressure were predictors of clinical benefit, whereas but no clinical factors were associated with the outcome of biochemical benefit (data not shown), suggesting that clinical outcome depended on preoperative clinical findings, whereas biochemical outcome was determined by only AVS LI.

Notably, 60% of patients with available clinical and biochemical outcome data, respectively, showed a surgical benefit in clinical and complete success in biochemical among the patients with an LI of 2 to 4 (Fig. 1). Although an LI > 4 is the most commonly used AVS criterion, approximately one-half of the reference centers in the Adrenal Vein Sampling International Study used more permissive LI values, ranging from 2 to 4 [19]. We found a favorable tendency, albeit not a substantial association, for a clinical benefit in patients with these LI values who also had higher systolic blood pressure, higher defined daily dose of antihypertensive medications, or lower serum potassium levels. We also found that younger patients achieved a good biochemical outcome more frequently than did older patients ($P < 0.01$) (data not shown); however, on AVS finding, contralateral aldosterone suppression was not associated with surgical benefits in terms of clinical and biochemical outcomes (data not shown). Additionally, we have reported that LI between 2 and 4 can be found even in patients with negative confirmatory testing for PA [21]. Therefore, clinicians could send patients in these LI zones to surgery with careful consideration for patient characteristics. However, the results should be carefully interpreted because of the small number of patients and that only selected patients underwent surgery in this subgroup.

Contralateral aldosterone suppression has been secondarily used by a decision criterion for laterality of hyperaldosteronism followed in LI [5, 22]. In the present study, a criterion of CLR < 1 was not associated with outcomes in terms of complete biochemical success and clinical benefit. However, a criterion for positivity of CLR < 1 showed high proportion of a surgical benefit equal to that of LI > 10, suggesting that a certain number of patients with
CLR > 1 showed complete success of biochemical outcome. Therefore, a more permissive
cutoff of CLR for a decision criterion of aldosterone laterality during non-ACTH stimulated
AVS might be adopted.

When comparing our results with those of PASO study [12], the proportion of patients who
achieved a surgical benefit in terms of clinical outcome was smaller in our study (70% vs 84%).
This may be because of the slightly older age and lower systolic blood pressure of our
participants (Table 1). Additionally, biochemical outcome was smaller in our study compared
with the PASO study [12]. This may have occurred because an ARR cutoff of 20 for screening
in Japan’s guideline [16] has been set, aiming at higher sensitivity to avoid false negatives
and to not to overlook PA patients. The cutoff, however, may affect the biochemical outcome
after surgery. Furthermore, our patients showed wide SD of ARR (mean, 103; interquartile
range, 55.1 to 212; range, 8.2 to 1890), indicating an overlap with the normal range. Routine
confirmatory testing may be needed when the ARR is positive after surgery, as suggested by
the PASO study. Additionally, a high prevalence of positive KCNJ5 mutation has been
reported in Japan [23]. Because KCNJ5-mutated aldosterone-producing adenoma have the
specific features of high CYP11B1 and low CYP11B2 [24], this may affect the lateralization of
PA by AVS. Finally, racial difference and high salt intake may be related to poor biochemical
outcomes by forming bilateral hyperplasia with asymmetrical aldosterone production. In
patients who had available data for pathological findings and assessment of biochemical
outcome after surgery, 70% were diagnosed with aldosterone-producing adenomas based on
the histological presence of adenoma and complete biochemical success after surgery. Some of
the remaining patients might have aldosterone-producing lesions; histological details wait
for further analysis.

4. Limitations

Our study has several limitations, with the main one being its retrospective nature. A second
limitation is that, although a surgical indication is based essentially on the Japan Endocrine
Society guidelines, details of the indication criteria used for adrenal surgery have not been
completely standardized among centers. For this reason, our study included a heterogeneous
patient population. A prospective standardized protocol study is needed to validate our results.
A third limitation is the protocol used for cosyntropin administration. Cosyntropin adminis-
tration is debated because it improves the AVS [25], whereas it lost lateralization of aldosterone
excess in some cases. There are many reports of the usefulness of noncosyntropin-stimulated
AVS in expert centers worldwide [19]; hence, our results apply only to patients with cosyntropin-
stimulated AVS. A fourth limitation is the small number of patients in the group with no
biochemical success.

5. Conclusion

Our study demonstrated the correlation between LI of AVS and postoperative outcomes using
the standardized criteria. The results provided evidence that LI cutoff of 4 is to determine
unilateral disease and to achieve good biochemical outcome, whereas the difference of clinical
benefit for LI between 4 and 10 and that for LI > 10 was relatively small. Our study validated
by standardized outcome measure that an LI > 4 recommended by clinical guidelines may be
appropriate for determining unilateral disease in PA.

Acknowledgments

Financial Support: This study was supported in part by Grants JP17ek0109122 and JP18ek0109352
for the Japan Primary Aldosteronism Study from the Practical Research Project for Rare/Intractable
Disease from the Japan Agency for Medical Research and Development (to M.N.), by Grants 27-1402 and
30-1008 from the National Center for Global Health and Medicine, Japan (to M.N.), and Grant 17K16173
Grant-in-Aid for Young Scientists (B) (to H.U.).
Correspondence: Mitsuhide Naruse, MD, PhD, Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan. E-mail: mnaruse@kyotolan.hosp.go.jp.

Disclosure Summary: The authors have nothing to disclose.

References and Notes

1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giachetti G, Letizia C, Maccario M, Mammaccia F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, Investigators PS; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48(11):2293–2300.

2. Käyser SC, Dekkers T, Groenevoud HJ, van der Wilt GJ, Carel Bax J, van der Wel MC, Herms AR, Lenders JW, Deinum J. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab. 2016;101(7):2826–2835.

3. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–4833.

4. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, Quinkler M, Hanslik G, Lang K, Hahn S, Allolio B, Meisinger C, Holle R, Beuschlein F, Bidlingmaier M, Endres S; German Conn’s Registry-Else Kröner-Fresenius-Hyperaldosteronism Registry. Observational study mortality in treated primary aldosteronism: the German Conn’s registry. Hypertension. 2012;60(3):618–624.

5. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.

6. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, Mantero F, Pessina AC. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62(1):62–69.

7. Auchus RJ, Wiens FH Jr, Anderson ME, Dolmatch BL, Trimmer CK, Josephs SC, Chan D, Toomay S, Nwariaku FE. What we still do not know about adrenal vein sampling for primary aldosteronism. Horm Metab Res. 2010;42(6):411–415.

8. Webb R, Mathur A, Chang R, Baid S, Nilubol N, Libutti SK, Stratakis CA, Kebebew E. What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism? Ann Surg Oncol. 2012;19(6):1881–1886.

9. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136(6):1227–1235.

10. Mulatero P, Bertello C, Sukor N, Gordon R, Rossato D, Daunt N, Leggett D, Mengozzi G, Veglio F, Stowasser M. Impact of different diagnostic criteria during adrenal vein sampling on reproducibility of subtype diagnosis in patients with primary aldosteronism. Hypertension. 2010;55(3):667–673.

11. Steichen O, Zinzindohoué F, Plouin PF, Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res. 2012;44(3):221–227.

12. Williams TA, Lenders JW, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prebijaz S, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: a review. J Clin Endocrinol Metab. 2018;103(3):900–908.

13. Umakoshi H, Tsuchiya N, Hyakusoku S, Kishida A, Iinuma M, Nakashima N, Matsumoto T, Hasegawa T, Hasegawa Y, Takamatsu H, Tsuchida A, Morishita S, Kusano S, Shibata H, Kameyama M, Ogawa Y, Kawashima T, Sone T, Inagaki N, Takahashi K, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kameyama M, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Yano T, Suzuki T, Naruse M. Significance of computed tomography and serum potassium in predicting subtype diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2012;98(3):969–999.

14. Wollny M, Gordon RD, Pimenta E, Daunt N, Slater GJ, Ahmed AH, Stowasser M. Repeating adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma. J Hypertens. 2013;31(10):2005–2009.

15. Shihiyama Y, Wada N, Umakoshi H, Ichijo T, Fujii Y, Kameyama K, Kai T, Sakamoto R, Ogo A, Matsuda Y, Fukukawa T, Tsuiki M, Suzuki T, Naruse M. Bilateral aldosterone suppression and its resolution in adrenal vein sampling of patients with primary aldosteronism: analysis of data from the WAVES-J study. Clin Endocrinol (Oxf). 2016;85(5):696–702.
16. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society. Guidelines for the diagnosis and treatment of primary aldosteronism—the Japan Endocrine Society 2009. Endocr J. 2011;58(9):711–721.

17. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaiizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashiwara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S; Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res. 2014;37(4):253–390.

18. Umakoshi H, Wada N, Ichiyo T, Kamemura K, Matsuda Y, Fuji Y, Kai T, Fukuoka T, Sakamoto R, Ogo A, Suzuki T, Tsuiki M, Naruse M; WAVES-J Study Group. Optimum position of left adrenal vein sampling for subtype diagnosis in primary aldosteronism. Clin Endocrinol (Oxf). 2015;83(6):768–773.

19. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J Jr, Wu KD, Wu VC, Pessina AC. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97(5):1606–1614.

20. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.

21. Umakoshi H, Naruse M, Wada N, Ichiyo T, Kamemura K, Matsuda Y, Fujiy Y, Kai T, Fukuoka T, Sakamoto R, Ogo A, Suzuki T, Naruse M; WAVES-J Study Group. Adrenal venous sampling in patients with positive screening but negative confirmatory testing for primary aldosteronism. Hypertension. 2016;67(5):1014–1019.

22. Wolley MJ, Gordon RD, Ahmed AH, Stowasser M. Does contralateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study. J Clin Endocrinol Metab. 2015;100:1477–1484.

23. Kitamoto T, Suehata S, Matsuzawa Y, Saito J, Omura M, Nishikawa T. Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas. J Atheroscler Thromb. 2015;22(2):191–200.

24. Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol. 2015;411:146–154.

25. Monticone S, Satoh F, Giachetti G, Viol A, Morimoto R, Kudo M, Iwakura Y, Ono Y, Turchi F, Paci E, Veglio F, Boscaro M, Rainey W, Ito S, Mulatero P. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension. 2012;59(4):840–846.